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Abstract
Background: Schizophrenia patients frequently develop somatic co-morbidity. Core tasks for GPs
are the prevention and diagnosis of somatic diseases and the provision of care for patients with
chronic diseases. Schizophrenia patients experience difficulties in recognizing and coping with their
physical problems; however GPs have neither specific management policies nor guidelines for the
diagnosis and treatment of somatic co-morbidity in schizophrenia patients. This paper
systematically reviews the prevalence and treatment of somatic co-morbidity in schizophrenia
patients in general practice.
Methods:  The MEDLINE, EMBASE, PsycINFO data-bases and the Cochrane Library were
searched and original research articles on somatic diseases of schizophrenia patients and their
treatment in the primary care setting were selected.
Results: The results of this search show that the incidence of a wide range of diseases, such as
diabetes mellitus, the metabolic syndrome, coronary heart diseases, and COPD is significantly
higher in schizophrenia patients than in the normal population. The health of schizophrenic patients
is less than optimal in several areas, partly due to their inadequate help-seeking behaviour. Current
GP management of such patients appears not to take this fact into account. However, when
schizophrenic patients seek the GP's help, they value the care provided.
Conclusion: Schizophrenia patients are at risk of undetected somatic co-morbidity. They present
physical complaints at a late, more serious stage. GPs should take this into account by adopting
proactive behaviour. The development of a set of guidelines with a clear description of the GP's
responsibilities would facilitate the desired changes in the management of somatic diseases in these
patients.
Background
Patients suffering from chronic psychotic disorders run an
increased risk of developing somatic diseases. These
chronic psychotic disorders include schizophrenia,
schizoaffective disorders, bipolar disorders and recurrent
psychotic depressions. Schizophrenia patients, especially,
run a higher risk of disease and early death [1]. Multiple
factors contribute to this risk [2-5]. Intrinsic causes are the
mental and physical stress accompanying the disorder, as
well as the negative symptoms, such as cognitive retarda-
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tion and loss of initiative. Extrinsic causes include
unhealthy life style, smoking, consumption of fast food,
lack of exercise and the side effects of pharmacotherapy
[6]. Antipsychotic medication also increases the chance of
developing metabolic syndrome and diabetes mellitus
[7].
Leucht et al. indicated, in their comprehensive review of
the literature, four causes for the increased physical co-
morbidity in patients with schizophrenia: disease-related
factors, drug treatment-related factors, system-related fac-
tors including stigmas on mental illnesses, and physician
related factors [8].
The majority of schizophrenia patients contact the general
practice rather frequently [9], yet they often face delay in
diagnosis and treatment of somatic co-morbidity [10].
GPs need to be better informed about the increased risk of
somatic co-morbidity in these patients in order to be able
to provide adequate health care for them [8]. Addition-
ally, it has been recognised that there is much room for
improvement in the collaboration between primary and
secondary care [11,12].
Currently, GPs have no guidelines on how to manage
somatic morbidity in patients with chronic psychosis. It is
supposed that the development and implementation of a
set of guidelines would improve the quality of care for
schizophrenia patients. An improvement could be
achieved if these guidelines addressed the deficiencies in
the care of GPs for these patients. Therefore it was decided
to collect data on somatic co-morbidity in patients with
chronic psychosis and on their treatment in general prac-
tice with the objective of determining the need for a spe-
cific set of guidelines for GPs.
The following questions were posed:
- What is the prevalence of somatic co-morbidity
among schizophrenia patients in general practice?
- Does the primary care provided for somatic diseases
meet the needs of these patients?
Method
A search was made of literature published between 1990
and September 2007 in the medical databases MEDLINE,
EMBASE, PsychINFO and the Cochrane Library. Very few
articles were found concerning schizophrenia patients in
general practice and therefore a wider search was con-
ducted using the key words 'mental disorders' OR 'psycho-
sis' OR 'schizophrenia' AND 'somatic problems' OR
'physical illness' OR 'physical disease' OR 'diabetes melli-
tus' OR 'cardiovascular disease' AND 'general practice' OR
'general practitioner' OR 'family physician' OR 'family
practice'. As a result 186 abstracts were found and from
these were selected the original research articles concern-
ing schizophrenia patients from the general population,
casu quo the patients in ambulatory care who constitute
the population of primary health care. From the bibliog-
raphies of these articles, more articles were selected based
on their relevance to family health care practice. The study
was restricted to articles on health problems that required
the GP to decide on treatment policies. Articles on general
quality of life were excluded, as were research articles
referring to mortality or abnormal laboratory values with-
out health problems. From studies that addressed multi-
ple questions, only those conclusions that were relevant
to the two research questions were considered.
Articles were selected by the authors, independently of
each other. The two lists of selected articles were com-
pared and, following discussions, consensus was reached
as to which articles should be included in the study and
which should be rejected. There was disagreement over
one article but it was finally excluded as it was not appli-
cable to primary care. A record sheet was developed to
present the relevant information from each study accu-
rately.
Results
A total of 15 original research articles on somatic co-mor-
bidity in patients suffering from psychotic disorders and 6
original research articles concerning diagnostic proce-
dures and treatment of somatic co-morbidity form the
basis of this paper.
Prevalence of co-morbidity (table 1)
Research articles on somatic co-morbidity comprised 6
database studies, 5 cross-sectional studies, one cohort
study, two nested case-control studies, and one case-con-
trol study. The database studies included large retrospec-
tive studies from 4 general practitioners' databases: 3 from
the UK and 1 from Italy, 1 national database from Fin-
land's National Hospital Discharge and Disability Pen-
sion registers, and 3 databases from social insurance
organisations in the USA. The research data from Meyer et
al came from the Clinical Antipsychotic Trials of Interven-
tion Effectiveness (CATIE) study base file. It was decided
to include this study since the data came from a cohort of
non-admitted schizophrenic patients.
The prevalence of chronic physical illnesses among
patients with severe mental illness (SMI) was found to be
high. Jones et al. found it to be as high as 74% in a small
cross-sectional comparative study among 147 Medicaid
enrolled patients (mean age ± SD of 38 ± 10 years) with
severe mental illness [13]. In this study chronic pulmo-
nary illness was the most prevalent (31% incidence).
However, this diagnosis was more frequently given toBMC Family Practice 2009, 10:32 http://www.biomedcentral.com/1471-2296/10/32
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Table 1: Somatic co-morbidity of schizophrenia patients
First author Period Design N Results Conclusion
Jones, 2004 [13]. 
USA
1996–2000 Cross-sectional 
comparative study of 
Medicaid claims
147 pts with SMI 
(78 schizophr. pts)
Prevalence: 74% of 
pts with SMI were 
treated for a chronic 
physical health 
problem. 50% had two 
or more chronic 
physical diseases. 
Chronic pulmonary 
disease was most 
prevalent: 31%
Risk adjustment for 
physical health is 
essential when setting 
performance standards 
or cost expectations 
for mental health 
treatment.
Dixon, 2000[14]. 
USA
1991–1996 Retrospective analysis 
of 2 databases and 
interviews (PORT)
Medicaid 6066;
Medicare 14182;
PORT 719
Prevalence: 
Schizophr. pts treated 
for DM: 9–14%. DM in 
schiz. pts. aged 65+: 
18.8–20.8%; DM in 
schizophr. women: 
15%–21.9%; DM in 
schizophr. black pts: 
11.6–18.5%
Before the widespread 
use of the atypical 
antipsychotic drugs, 
diabetes was a major 
problem for persons 
with schizophrenia. 
Being older, female, or 
black increased the 
likelihood of DM.
Carlson, 2006[15]. 
UK
1994–2002 Retrospective cohort 
study in UK General 
Practice Research 
Database
59089 conv. antipsych 
users; 9053 atyp 
antipsych users; 
1491548 ctrls
HR of DM: conv. 
antipych: 1.9; atyp. 
antipsych: 2.9
There is an increased 
risk of developing 
diabetes during 
treatment with 
antipsychotics.
Sacchetti, 2005[16]. 
Italy
1996–April 2002 Retrospective age- 
and sex-matched 
cohort study in a 
general practitioners 
database
2071 haloper.
266 olanzap.
567 risperid.
109 quetiapine
6012 ctrls
HR of DM conv. 
antipsych: haloperidol: 
12.4; atyp antipsych: 
olanzapine: 20.4; 
risperidone: 18.7; 
quetiapine: 33.7
The incidence of 
diabetes is significantly 
higher in patients taking 
antipsychotics.
Kornegay, 2002[17]. 
UK
1994–1999 Nested case-control 
study in UK General 
Practice Research 
Database
424 newly diagnosed 
DM pts vs. 1522 ctrls
OR of current 
antipsych. exposure in 
pts. with incident DM: 
1.7
This study showed an 
increased risk of 
incident diabetes 
among current users of 
atypical and 
conventional 
antipsychotic 
medication.
Meyer, 2005 [18]. 
USA
2001–June 2003 Cohort study, using 
baseline data from 
CATIE Schizophrenia 
Trial
1231 schizophr. pts
18–65 years of age
Prevalence of 
metabolic syndrome in 
schizophr. pts: 35.8%. 
Pts with metab. syndr. 
rate themselves lower 
on physical health.
The metabolic 
syndrome is highly 
prevalent in schizophr. 
pts and is strongly 
associated with a poor 
self-rating of physical 
health and increased 
somatic preoccupation.
Lamberti, 2006[19]. 
USA
Not mentioned Cross-sectional 
comparative study
93 clozapine users vs. 
2701 ctrls
Prevalence of 
metabolic syndrome: 
clozapine: 53.8%; 
controls: 20.7%
Patients receiving 
clozapine are at 
significantly increased 
risk for developing the 
metabolic syndrome.
Osborn, 2006[20]. 
UK
2003 Cross-sectional 
screening
74 pts with SMI vs. 48 
ctrls
OR of raised 10-years 
CHD risk among 
patients with SMI: 1.8; 
OR of raised chol/HDL 
ratio: 1.8. OR of DM: 
3.8. OR of smoking: 
3.0
Patients with non-
affective chronic 
psychotic illness have 
excess risk factors for 
coronary heart disease, 
which are not wholly 
accounted for by 
medication or socio-
economic deprivation.BMC Family Practice 2009, 10:32 http://www.biomedcentral.com/1471-2296/10/32
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Samele, 2007[21]. 
UK
1999–2001 Case-control study of 
first episode psychosis 
(FEP) patients
89 FEP pts vs.
89 ctrls matched on 
age and sex
OR of current physical 
illness: 2.85. OR of 
smoking: 1.82. OR of 
eating fast-food: 1.04
Some risk factors for 
physical health 
problems are present 
at the onset of 
psychosis, but these 
may be explained by 
unemployment.
Himelhoch, 2004[22]. 
USA
Mrt 2000–Dec 2000 Cross- sectional 
comparative survey
185 SMI pts vs. 2706 
ctrls matched on age, 
gender, and race
Prevalence of: 
current smoking 60,5%, 
COPD 22.6%, astma 
18.5%
Prevalence of COPD is 
significantly higher 
among patients with 
SMI. Predictive factors 
were age, being male, 
and being a current 
smoker.
Carney, 2005[23]. 
USA
1996–2002 Retrospective analysis 
of longitudinal claims 
data
1074 pts with 
schizophr. or 
schizoaffective 
disorder vs. 726262 
ctrls
OR of: COPD 1.88, 
complicated DM 2.11, 
hypothyreoidism 2.62, 
hepatitis C 7.54, 
electrolytdisorders 
4.21
Schizophrenia is 
associated with 
substantial chronic 
medical burden. 
Familiarity with 
conditions affecting 
schizophr. pts may 
assist programs aimed 
at providing medical 
care for the mentally ill.
Lichtermann, 
2001[24]. Finland
1971–1996 Cohort study 26.996 schizophr. pts, 
39131 parents, 52976 
siblings
SIR of: cancer 
incidence 1.17, lung 
cancer 2.17, pharynx 
cancer 2.60
Schizophr. pts have an 
increased risk of 
pharynx- and lung 
cancer. This may be the 
consequence from 
lifestyle factors, 
particularly tobacco 
smoking and alcohol 
consumption.
Hippisley-Cox, 2007 
[25]. UK
1995–2005 Population-based 
nested case-control 
study
139 schizophr. pts vs. 
571 ctrls
OR of mamma ca 1.52, 
colon ca 2.90, 
respiratory ca 0.53
Schizophr. pts have a 
higher risk of colon 
cancer and a lower risk 
of respiratory cancer 
compared with 
controls after 
adjustment for 
confounders.
Kuritzky, 1999[26]. 
Israël
1999 Cross-sectional 
comparative survey
108 schizophr. pts vs. 
100 ctrls
Prevalence of 
headache in pts: 48%; 
headache in ctrls: 41%. 
No sign. difference on 
comparing the type of 
headache between 
groups.
Schizophr. pts describe 
the same type, 
frequency, severity and 
duration of headache 
compared with 
controls, but tend to 
refrain from 
complaining about their 
headache.
Viertiö, 2007[27]. 
Finland
Sept 2000–June 2001 Cross-sectional 
comparative study
Distance VA 
measured: 56 
schizophr. pts vs. 
6588 ctrls.
Near VA measured: 
51 schizophr. pts vs. 
6415 ctrls
OR of schizophr. pts 
with visual impairment 
for distance: 5.04 and 
for near vision: 6.22 
Prevalence of 
schizophr. pts having 
visual examination 
during previous 5 
years: 43.9%. vs. total 
sample: 69.7%
Schizophr. pts attend 
visual examinations less 
frequently than others, 
and their vision is 
notably weaker. 
Regular ocular 
evaluations should be 
included in physical 
health monitoring.
HR = Hazard Ratio
OR = Odds Ratio
SIR = standardized incidence ratio
DM = diabetes mellitus
SMI = severe mental illness
VA = visual acuity
Table 1: Somatic co-morbidity of schizophrenia patients (Continued)BMC Family Practice 2009, 10:32 http://www.biomedcentral.com/1471-2296/10/32
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patients with an affective psychosis than to schizophrenia
patients. Infectious diseases caused the highest average
annual costs of treatment, and were often associated with
substance abuse and homelessness. Age, obesity, and sub-
stance abuse were predictive of health problem severity.
Diabetes mellitus
Diabetes mellitus was the first chronic disease to be recog-
nised in schizophrenic patients and in patients who use
antipsychotic drugs. Also, a much higher prevalence of
diabetes mellitus (9–14%) was found in 5 studies, from
three different countries, of which the study of Kornegay
et al. was prospective, and the other 4 retrospective [13-
17]. The relative risk of developing diabetes mellitus is 2–
3 times higher in schizophrenic patients than in non-
schizophrenic. Dixon et al. carried out a study using two
large insurance databases in the USA, Medicaid and Medi-
care, and also interviewed 719 schizophrenic patients in
two states. The patients had been diagnosed with schizo-
phrenia, including both schizoaffective and schizophreni-
form disorders. The prevalence of current treated diabetes
varied from 9 to 14 percent. Being older, female, and Afri-
can-American was associated with an increased likelihood
of diabetes. Dixon's study, in the early 1990s, suggests that
even before the widespread use of atypical antipsychotic
drugs, diabetes was a major problem for persons with
schizophrenia [14].
Carlson et al. reports the results of a retrospective cohort
study to determine the incidence of diabetes mellitus in
patients exposed to conventional or atypical antipsychotic
drugs compared to a general practice population in the
UK General Practice Research Database. The incidences of
diabetes during exposure to conventional antipsychotic
drugs was 7.7 per 1000 patient-years (CI = 6.7–8.7) and
9.8 per 1000 patient-years (CI = 7.4–12.2) during expo-
sure to atypical antipsychotic drugs. This is significantly
higher than the incidence of diabetes in the patient popu-
lation of the General Practice Research Database, which
was 3.3 [15].
Sacchetti et al. also carried out a retrospective cohort study
in an Italian general practice database [16]. They com-
pared subjects who were exposed and not exposed to
antipsychotic drugs. They compared the incidence of dia-
betes (per 1000 person-years) in patients taking haloperi-
dol (N = 2071), olanzapine (N = 266), risperidone (N =
567) and quetiapine (N = 109) with a control group (N =
6026). The ratios found were: 12.4% for the haloperidol
group, 20.4% for the olanzapine group, 18.7% for the ris-
peridone group, and 33.7% for the quetiapine group. The
four treatment groups differed too much in size to draw
specific conclusions about each single drug.
Kornegay et al. carried out a nested case-control study in
UK General Practice Research Database among adults pre-
scribed at least one course of treatment with an antipsy-
chotic drug between January 1994 and December 1998
and compared them with age, gender and practice
matched controls [17]. The results showed elevated risk of
incident diabetes (Odds ratio 1.7) associated with current
exposure to atypical or conventional antipsychotic drugs,
independent of the risk due to other established risk fac-
tors.
Cardiovascular risk factors
Schizophrenia patients have a higher chance (prevalence
of 36%) of developing metabolic syndrome, even without
antipsychotic medication. This is generally accompanied
by a poor self-experienced physical health [18]. Lamberti
et al. conducted a cross-sectional comparative study
which showed an additional increased risk of 53.8% for
metabolic syndrome among users of clozapine, versus
20.7% in the control [19]. Not only diabetes mellitus but
multiple risk factors for cardiovascular diseases are signif-
icantly increased in this patient group [20]. Schizophrenic
patients have a higher risk of raised cholesterol/HDL ratio,
and also smoke more often.
Some risk factors are already present at the onset of the
psychotic disorder. Samele et al. compared eighty-nine
patients with a first episode psychosis (FEP) to age- and
sex matched controls for self-reported physical illness and
health risk factors [21]. Patients with a first episode psy-
chosis were more likely to be cigarette smokers and eat
fast food, although these risk factors may be explained by
unemployment.
Respiratory system
Respiratory problems, COPD and a deteriorated lung
capacity occur significantly more frequently [21-23].
Himelhoch et al. interviewed a sample of SMI patients
(60% were current smokers, mean age 44 years), and com-
pared the results to a matched subset of national compar-
ison subjects. The self-reported prevalence of COPD
among schizophrenic patients was 22.6%. Carney et al
analysed longitudinal administrative claim data of schiz-
ophrenia patients and controls and found an OR of 1.88
for COPD [23].
Other co-morbidity
Besides COPD, Carney et al. found in their large database
study an increased risk of the following conditions:
hypothyroidism, hepatitis C and electrolyte disorders
[23]. Lichtermann et al. found an increased risk of phar-
ynx- and lung cancer in their large-scale Finnish database
study [24], but Hippisley-Cox et al. found in their small
case-control study a lower risk of respiratory cancer, and a
higher risk of mamma cancer and colon cancer [25].
When asked, schizophrenic patients appear to suffer from
migraines and tension headaches as much as the control
group [26]. However, they did not report this spontane-BMC Family Practice 2009, 10:32 http://www.biomedcentral.com/1471-2296/10/32
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ously and they usually sought help quite late. This is also
shown by the fact that schizophrenia patients had much
more deteriorated vision both for distance and for near
vision, because they were less likely to visit an ophthal-
mologist or optician when their eyesight was impaired
[27].
Screening, diagnostic procedures and treatment of somatic 
co-morbidity (table 2)
Two cohort studies and one case-matched retrospective
review dealt with the level of health-care provision for
psychotic patients, and three studies examined patients'
views on diagnostic procedures and physical health care.
Tsay et al. conducted research among a large number of
acute patients with appendicitis [28]. They showed that
schizophrenia patients had a 2.8 increased chance of a
ruptured appendix at the start of the treatment. In addi-
tion, in schizophrenia patients chronic diseases like
hypertension, dyslipidaemia and DM were under-diag-
nosed and under-treated (30–88%) [29]. Roberts et al.
reviewed case notes of 195 schizophrenia patients and
390 matched controls [30], and found that schizophrenia
patients were significantly less likely to have had their
blood pressure or cholesterol recorded. GPs often
appeared not to be aware of the risk of somatic co-mor-
bidity in schizophrenia patients, and they knew little of
the side-effects of antipsychotic medication [31].
Osborn et al. invited 182 schizophrenia patients and 313
controls for a cardiovascular risk assessment in general
practice. The interest in risk assessment among the psy-
chotic patients was higher than the researchers expected,
but lower than the control group: odds ratio 0.76 (0.53–
1.10) [32]. The psychosis group consulted their GPs more
often – mean difference 1.8 (0.8–2.9) per year.
Beecroft et al. investigated whether SMI patients received
better health treatment if they attended their GP, a Com-
munity Mental Health Team, or both. They interviewed
309 patients with psychotic disorders. Patients who had
seen their GP in the previous 6 months were more likely
to be satisfied with the service provided for their physical
health. They suggested that the health needs of schizo-
phrenic patients might be better met if the GP adopted a
more proactive follow-up policy which encouraged the
patient to see their GP who was responsible for physical
health service provision [33].
Discussion
The data show that the prevalence of somatic morbidity in
patients with chronic psychosis is indeed considerably
higher than in an open population [34]. This somatic
morbidity concerns a scala of diseases ranging from diabe-
tes mellitus to hepatitis C.
Patients with chronic psychosis are at risk of under-diag-
nosis and under-treatment. The nature of their mental ill-
ness makes it difficult for these patients to interpret body
signals correctly. Moreover, schizophrenia patients are not
inclined to discuss complaints spontaneously and find it
difficult to call for help, while some patients do not like
others to interfere [35]. Both chronic and acute conditions
surface at a late stage. In addition to this, the illness is
accompanied by negative symptoms and cognitive deteri-
oration, which lead to inactivity and loss of initiative. This
contributes to higher risks of poor attendance and self
care. Schizophrenic patients have trouble adjusting to
society's demands, which causes stress. In order to cope
with this stress and the psychotic symptoms, they take ref-
uge in nicotine, cannabis, alcohol and other narcotics.
Unfortunately, the use of substances to self-medicate may
exacerbate the psychotic symptoms, thus creating a
vicious cycle, which leads to an existence on the edge of
society.
The above-mentioned limitations make these patients less
inclined to request medical assistance [35,36]. As a conse-
quence, the health of schizophrenic patients suffers in sev-
eral areas. However, when schizophrenic patients seek
GP's assistance, the care provided is highly valued [37,38].
Patients who visit the GP regularly are often satisfied with
the care provided and their health needs may be better
met if the GP applied a more proactive follow-up policy
which encouraged the patients to see their GP [32,33].
Patients with severe mental disease, suffer from a loss of
perspective and loss of hope. These are patient-related fac-
tors which might play a role in their appreciation of diag-
nostic procedures. No evidence of any research has been
found that explores the role of these factors in the tacit
understanding between the GP and his patient.
Compassion and offering an easily-accessible care for
patients are priorities for GPs [39]. They know from expe-
rience that coming too close to a psychotic or paranoid
patient can result in his withdrawal from medical care.
The GP needs to balance between offering the necessary
care without losing contact with the patient.
Limitations
A few studies dealt with patients suffering from 'severe
mental illness' (SMI); the SMI label comprises a hetero-
genic group that largely consists of psychotic patients.
Four studies concerned the somatic co-morbidity in antip-
sychotic drugs users, and three studies examined insur-
ance claims data.
Most of the studies that were included came from the
United Kingdom (n = 9) and the United States (n = 7);
two articles came from Finland, one from Italy, one fromBMC Family Practice 2009, 10:32 http://www.biomedcentral.com/1471-2296/10/32
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Table 2: Screening, diagnostic procedures and treatment of somatic co-morbidity
First author Period Design N Results Conclusion
Tsay, 2007 [26].
Taiwan
1997–2001 Cohort study 97589 pts admitted 
for acute appendicitis
OR of perf. appendix: 
no mental disorder: 
1.0; schizophr. pts: 
2.83; affective 
psychosis: 1.15; other 
mental disorders: 1.58
Mentally ill patients are 
at a disadvantage in 
obtaining timely 
treatment for their 
physical diseases. 
Schizophrenic pts are 
the most vulnerable 
ones for obtaining 
timely surgical care.
Nasrallah, 2006[27].
USA
2003 Cohort study, 
baseline data from 
CATIE Schizophrenia 
Trial
1460 schizophr. pts 
18–65 years of age
Prevalence of pts 
with untreated DM: 
30.2%; pts with 
untreated 
hypertension: 62.4%; 
pts with untreated 
dyslipidemia: 88.0%
There is a high 
likelihood that 
metabolic disorders 
are untreated in 
schizophr. pts.
Roberts, 2007[28].
UK
April 1998–Dec 2000 Case-matched 
retrospective review.
195 schizophr. pts vs. 
390 matched asthma 
pts vs. 390 matched 
controls
OR of blood pressure 
records 0.51 (vs. 
asthma pts); OR of 
cholesterol records 
0.50 (vs. asthma pts); 
OR of blood pressure 
records 0.68 (vs. 
controls); OR of 
cholesterol records 
0.58 (vs. controls)
Schizophr. pts are less 
likely to receive some 
important general 
health checks than 
patients without 
schizophrenia.
Wright, 2006[29].
UK
Not mentioned Qualitative research 31 SMI pts, 8 GP's and 
2 NP's, 25 mental 
health workers
Identified problems are 
the lack of familiarity 
with SMI and 
antipsychotic side 
effects in general 
practice, poor 
communication of 
physical health issues 
to the CMHT, lack of 
knowledge regarding 
CHD risk factor 
screening, and 
difficulties in 
interpreting screening 
results and 
implementing 
appropriate 
interventions in 
secondary care
Management of 
physical health care for 
people with SMI 
requires complex 
solutions that cross the 
primary-secondary 
care interface.
Osborn, 2003[30]. 
UK
Not mentioned Experiment 182 psychotic pts
313 controls
OR for pts 
participating in 
cardiovascular risk 
screening: 0.76. 
Psychotic pts consulted 
their GP more often 
(mean difference 1.8)
Interest in risk 
assessment was similar 
to those in other 
community research 
involving blood tests.
Beecroft, 2001[31]. 
UK
Not mentioned Interviews 309 randomly selected 
pts from a sample of 
566 psychotic pts
Pts who visited their 
GP within the last 6 
months were more 
often (83% vs. 50%) 
satisfied with the 
amount and type of 
service provided for 
their physical needs
Patients with SMI 
should be encouraged 
to see their GPs. There 
is a strong argument 
for a routine annual 
check up of the 
severely mentally ill by 
their GPs.
OR = Odds ratio
SMI = severe mental illness
CMHT = community mental health teams
CHD = coronary heart diseaseBMC Family Practice 2009, 10:32 http://www.biomedcentral.com/1471-2296/10/32
Page 8 of 9
(page number not for citation purposes)
Israel, and one from Taiwan. In the health care system of
these countries the GPs provide all primary health care,
although the position and functions of GPs might be
somewhat different. Our results cannot be generalized to
countries with other healthcare systems.
The methodology of the studies enclosed varied mark-
edly, thus resulting in evidence of varying strength. The
studies of Kornegay, Samele and Hippisley-Cox, being
case-control studies, provide the best quality of evidence
with regard to the first research question, while Roberts'
study does so for the second research question. Although
the figures of the enclosed studies vary, it is emphasized
that the outcomes do not contradict each other, but all
come to the same conclusions with one exception: the risk
of lung cancer. The results of the enclosed studies were
presented in different outcome measures, e.g. odd ratios,
hazard ratios, Cox proportional hazard analysis, standard-
ized incidence ratios and prevalence statistics (percent-
ages). This made it impossible to calculate 'overall'
numbers.
Because it was felt necessary to add the search terms 'dia-
betes mellitus' and 'cardiovascular disease' to the search, it
is possible that these topics are overrepresented in our
study.
Conclusion
In the enclosed studies, patients suffering from schizo-
phrenia and related psychoses run a substantial risk of
developing diabetes mellitus, metabolic syndrome,
hypertension, cardiovascular diseases, lung diseases such
as COPD, hypothyroidism and visual problems. The
health of these patients is less than optimal in several
areas, due to disease-related factors, to drug treatment-
related factors, to patient-related factors, and to physician-
related factors.
GPs should be aware of the high risk of somatic co-mor-
bidity in this specific patient group and take into account
their cognitive and social handicaps by being alert and
proactive when diagnosing. While at the same time, how-
ever, GPs should also inquire after and respect the
patient's value judgement concerning screening, diagnos-
tic procedures, and treatment.
The development of a set of guidelines for GPs, giving a
clear description of responsibilities with regard to somatic
co-morbidity, would facilitate the necessary change in the
GP's management of and contribute to an improvement
in primary care for these patients.
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